Gavi's investment opportunity in numbers

Between 2000 and 2020, Gavi helped vaccinate over one billion children in the world's most vulnerable countries, saving more than 17 million lives. A child born in a Gavi-supported country is 70% less likely to die from a vaccine-preventable disease before their fifth birthday than in 2000.

Despite this progress, we live in a world where climate change is causing more extreme weather, conflict is forcing millions to flee, infectious diseases are on the rise and the next pandemic is on the cusp of becoming a global pandemic. So the next five years of Gavi's work will be a time when vaccines are more important than ever.

Gavi plans to vaccinate more children than ever before, against more diseases than ever before, faster than ever before. Here are the top nine numbers that define today's investment opportunity:

Since its founding 20 years ago, Gavi has worked with key partners to develop unique ways to deliver vaccines quickly and efficiently. By securing markets for vaccines, the Alliance has advanced vital research and development, ensuring more children have access to life-saving immunizations. Now, Gavi plans to work twice as fast: after helping to save $1 billion over 20 years, it plans to help save $1 billion over 10 years (500 million people over the next five years).

GAVI will accelerate efforts to reduce the number of so-called “zero-vaccine” children – those who have never received a vaccine – contributing to the Immunization Agenda 2030 target of a 50% reduction.

Gavi supports countries to increase vaccination coverage against infectious diseases that kill children. These vaccinations include pneumococcal, rotavirus, measles and pentavalent vaccines. Gavi is also planning its broadest portfolio of vaccines to date, which will include respiratory syncytial virus (RSV), tuberculosis, dengue, measles-rubella and hepatitis E next year.

Country ownership of national immunization programs is what drives Gavi's work. Working in partnership with countries, the Alliance has built a successful model that links donor investments with domestic health investments. Over the next five years, countries will pay for more than 40% of routine vaccine costs, up from just 10% 15 years ago. By 2030, more than one in four of the 78 low-income countries originally supported by Gavi will fully fund their own vaccine programs.

Gavi is ready to respond to 150 infectious disease outbreaks over the next five years. Global crises such as Ebola and the COVID-19 pandemic have taught us hard lessons. And through our experience with COVAX distributing COVID-19 vaccines to the world's most vulnerable people, Gavi has strengthened our capacity to help countries prevent, prepare and respond to evolving health threats. This is crucial and urgent. The number of infectious diseases Gavi will respond to is increasing from 15 in 2020 to 35 in 2023.

Gavi plans to lower prices for 50% of its vaccine portfolio between 2026 and 2030, while at the same time using market power to encourage innovation among manufacturers. Gavi has also helped reduce the costs of key vaccines. For example, the cost of a dose of rotavirus vaccine fell from $15.75 in 2010 to $3.27 by 2023. Over the same period, the cost of the pentavalent vaccine fell from $8.95 to $2.81 per dose. The Alliance minimizes costs for donors and countries by maintaining a small and efficient Secretariat, ensuring that 97 cents of every dollar goes directly to supporting vaccine programs.

Illness and death can impose a heavy economic burden on countries, both in health care costs and lost working age. Vaccines can save lives and bring significant economic benefits to individuals and countries by enabling people to live longer, healthier lives.

Gavi-supported immunization programmes in low-income countries have generated more than USD 220.5 billion in economic impact since 2000. As the Alliance prepares to vaccinate against more diseases, faster, it is expected to generate an additional USD 1 billion in economic impact between 2026 and 2030.

Gavi ensures that immunization is integrated into primary health care systems, connecting individuals to health services at every point of contact between them and the vaccine recipient. Linking to primary health care systems increases the chances of accessing health for life.

Cervical cancer claims the lives of approximately 350,000 women each year, more than 90% of which occur in low- and middle-income countries. However, cervical cancer is fully preventable with the effective (human papillomavirus) HPV vaccine. For every 1,000 girls vaccinated, approximately 18 deaths are prevented, making it one of the most impactful vaccines in Gavi's portfolio. Over the next five years, Gavi plans to vaccinate more than 120 million girls against HPV, saving 1.5 million lives.

Malaria is one of the leading causes of deaths worldwide among children under five, especially in low- and middle-income countries. The introduction of the malaria vaccine has been a major global health success in recent years. Gavi aims to reach 50 million children with the vaccine over five years.